Table 1 Overview of published trials on treatment efficacy and OS
From: Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches
First author (n: number of patients) | Compound used | Activity | PSA fall ≥ 50% | CT (RECIST) | PSMA PET | Symptomatic response | Biochemical/radiological PFS | Overall survival |
|---|---|---|---|---|---|---|---|---|
Vallabhajosula et al. 2005 [46] | 177Lu-J591 | 0.3–2.7 GBq/m2for 177Lu | NA | NA | NA | NA | NA | NA |
Lu (n: 35) = 177 | 90Y-J591 | 0.18–0.7 GBq/m2for 90Y | ||||||
n (28) = 90Y | ||||||||
Zechmann et al. 2014 [37] (n: 28) | 131I-MIP 1095 | 2.0–7.2 GBq | 61% | NA | NA | 23% CR | Median BPFS 126 days | NA |
PD 14% | 61% PR | |||||||
Ahmadzadehfar et al. 2015 [14] (n: 10) | 177Lu-PSMA-617 | 4.1–6.1 GBq | 50% | NA | NA | NA | NA | NA |
PD 30% | ||||||||
Ahmadzadehfar et al. 2016 [26] (n: 24) | 177Lu-PSMA-617 | 4.1–7.1 GBq | 42% | PR 40% | PR 80% | NA | NA | NA |
PD 21% | SD 55% | SD 0% | ||||||
PD 5% | PD 20% | |||||||
Kratochwil et al. 2016 [32] (n: 30) | 177Lu-PSMA-617 | 4–6 GBq | 43–72% | NA | NA | NA | NA | NA |
PD 27% | ||||||||
Baum et al. 2016 [51] (n: 56) | 177Lu-PSMA I&T | 3.6–8.7 GBq | 59% | PR 20% | PR 56% | 33% PR | Medial radiological PFS 13.7 months |  |
PD 11% | SD 52% | SD 8% | ||||||
PD 28% | PD 36% | |||||||
Rahbar et al. 2016 [25] (n: 74) | 177Lu-PSMA-617 | 6Â MBq | 31% | NA | NA | NA | NA | NA |
PD 23% | ||||||||
Rahbar et al. 2016 [39] (n: 28) | 177Lu-PSMA-617 | 7 MBq | 32–50% | NA | NA | NA | NA | 29.4 vs. 19.7 weeks |
PD 20% | ||||||||
Heck et al. 2016 [48] (n: 22) | 177Lu-PSMA-I&T | 7–7.8 GBq | 33% | PR 11% | Integrated CR 5% | 14% CR | Median PFS 175 days | NA |
PD 32% | SD 56% | SD 63% | 42% PR | |||||
PD 33% | PD 32% | |||||||
Yadav et al. 2017 [52] (n: 31) | 177Lu-PSMA-617 | 1.1–5.5 MBq | Mean pre and post |  | CR 33% | Analgesic score reduced from 2.5 to 1.8 | Median PFS 12 months | Median OS 15 weeks |
275/41 | PR 50% | |||||||
PD 20% | SD 17% (n = 6) | |||||||
Fendler et al. 2016 [23] (n: 15) | 177Lu-PSMA-617 | 6Â MBq | 60% | PR 27% | NA | NA | NA | NA |
SD 40% | ||||||||
PD 33% | ||||||||
Kratochwil et al. 2016 [36] (n: 2) | 225Ac-PSMA-617 | 4–6 GBq | 100% | NA | NA | NA | NA | NA |
Ahmadzadehfar et al. 2017 [27] (n: 52) | 177Lu-PSMA-617 | 5.6–6 MBq | 44% 1st cycle | NA | NA | NA | NA | Median OS 60 weeks |
59.6% | ||||||||
2nd cycle | ||||||||
59.6% 3rd cycle | ||||||||
Rahbar et al. 2017 [16] (n: 145) | 177Lu-PSMA-617 | 2–8 MBq | 45% | PR 45% | NA | NA | NA | NA |
SD 28% |